Genmab — August 2016
-
Jeg ser følgende kurstriggere resten af året: 1 Teknologiaftale på Duobody og/eller Hexabody. 2 Flere INDs på Duobodies. 3 Fase 2 data på dara i NHL. 4 Fase 1/2 data på tisotumab. 5 Højere Darzalex salg de kommende måneder. 6 Godkendelse af Darzalex i anden linie. Bare roligt der kommer til at ske en masse.
-
Det tyder ikke på vi skal frygte konkurrence fra Ninlaro

-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind